Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple surgical step make hysterectomies safer?

NCT ID NCT07774871

Disease control Sponsor: ClinAmygate Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial asks whether routinely identifying and protecting the ureters (the tubes that carry urine) during a laparoscopic hysterectomy for non-cancerous conditions is better than doing so only when needed. It compares operative time and safety between the two approaches in women aged 35-70. The goal is to see if routine ureterolysis improves surgical outcomes without adding significant risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Routine ureterolysis (a surgical procedure to identify and protect the ureters during hysterectomy)
What this could lead to
If routine ureterolysis proves safe and efficient, it could become a standard step in laparoscopic hysterectomies, potentially reducing ureter injuries.
What could go wrong
This is a single trial with 100 participants, so results may not apply broadly. Routine dissection could increase operative time or risk tissue damage, and the benefits over selective use are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Women aged 35-70 years Scheduled for TLH for benign indications: Symptomatic fibroids, Abnormal uterine bleeding, Adenomyosis, Endometrial hyperplasia, Pelvic organ prolapse requiring hysterectomy, Chronic pelvic pain, Uterine size ≤16 weeks Exclusion Criteria: * Previous pelvic radiation * Known ureteric abnormalities or pathology * Severe cardiopulmonary disease precluding laparoscopy * Inability to provide informed consent * Known retroperitoneal pathology * Emergency surgery * Uterine size \> 16 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenomyosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenomyosis pelvic organ prolapse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Total laparoscopic hysterectomy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kasr Alaini gynecology and obstetrics hospital

    Cairo, Cairo Governorate, 11472, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.